Freddy Caldera, DO, MS
Disclosures: Grant or research support-Takeda Pharmaceuticals (Any division) - 07/18/2022
PHS 398 (Rev. 9/04), Biographical Sketch Format Page

 

 

 

 

BIOGRAPHICAL SKETCH

 

 

NAME

Caldera, Freddy

POSITION TITLE

Associate Professor of Medicine (CHS)

eRA COMMONS USER NAME

fcaldera

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)

INSTITUTION AND LOCATION

DEGREE

(if applicable)

YEAR(s)

FIELD OF STUDY

University of Florida                               Gainesville, FL

BS

2000

Nutrition and Zoology

Des Moines University         Des Moines, IA

DO

2004

Doctor of Osteopathy

Providence Hospital            Southfield, MI

Internship

2005

Traditional Osteopathic Internship

University of Kentucky         Lexington, KY

Residency

2008

Internal Medicine

University of Kentucky         Lexington, KY

Fellowship

2011

Gastroenterology

University of Wisconsin       Madison, WI

Master

2018

Clinical Investigation

 

 

 

 


1

 

  1. Personal Statement

I am a formally trained clinical investigator, gastroenterologist, and physician scient who specializes in inflammatory bowel disease.   My primary research interest includes determining the risk of infections and evaluating the immune response to vaccines in immunosuppressed patients with IBD.   Infections are one of the most common complications in immunosuppressed patients. My goal is to optimize immunization strategies and vaccine use in patients with IBD, which affects 3 million people in the United States. I have expertise in designing and performing studies evaluating vaccine response in immunosuppressed patient with IBD.  I also have expertise in evaluating the risk of infection from immunosuppression in patients with IBD.  I also participate in numerous industry and foundation sponsored cohort studies Over the past two years my research productivity has increased publishing 28 peer review articles in that time focusing on vaccine response in patients with IBD Additionally, I was able to secure funding for our study “HERCULES”  HumoRal and CellULar initial and Sustained immunogenicity in patients with IBD” We have published our original analysis and have submitted our post third dose data to Inflammatory Bowel Diseases and our cell-mediated immune response to COVID-19 vaccines to the American Journal of Gastroenterology Obtaining this collaborative grant will help me by extending our study and establishing a collaborative group at UW that will be strategically positioned to obtain extramural funding evaluating immune response to vaccines in immunosuppressed populations.

 

 

 

 

  1. Positions and Honors

 

Positions and Employment

2002-2003                                          Assistant Professor of Spanish for Medical Professionals

Des Moines University, Des Moines, IA

2002-2003                                          University Student Government President Des Moines University

                                                                                    Des Moines, IA

2005-2008                                          Intern and Resident in Internal Medicine, University of Kentucky, Lexington, KY

2008-2011                                          Fellow in Gastroenterology, University of Kentucky Lexington, KY              

2010-2011                                          Chief Fellow in Gastroenterology University of Kentucky 

2011- Present       Assistant Professor of Medicine, University of Wisconsin School of Medicine and Public Health, Division of Gastroenterology and Hepatology.

 

Memberships

 

2008-Present                            Crohn’s and Colitis Foundation of America, Member

2008-Present                            American Gastroenterology Association, Member

2008-Present                            American College of Gastroenterology, Member

 

 

Honors and Awards

2002                                                                      Minority Scholarship Des Moines University

2003                                                                      Excellence award in Family Medicine Des Moines University

2005                                                                      Intern of the Month University of Kentucky Lexington, KY

2006                                                                      Internal Medicine Resident of the Month University of Kentucky

Lexington, KY

2016              American Gastroenterology Association Recognition of Early Stage Investigator

 

 

  1. Contribution to Science

 

Immune response to vaccines in patients with IBD. There is a paucity of studies evaluating the immune response of vaccines in patients with IBD. My research seeks to fill this gap by determining if patients with IBD might need an optimized immunization schedule. Initial studies suggested that immunosuppressed patients with IBD may have a blunted response to vaccines. I have shown that sustained protection is dependent on the type of vaccine.  Systemic immunosuppression doesn’t affect the sustained seroprotection to MMR (measles, mumps, and rubella), but may lower the response to Tdap (tetanus, diphtheria, and pertussis).  I designed a randomized control trial evaluating the high dose influenza vaccine which significantly induced higher postimmunization antibody levels in immunosuppressed patients with IBD.   Thus, an alternative immunization can improve vaccine response in patient with IBD.  Our initial study in patients with IBD has shown the most patients with IBD response to vaccines.

 

  1. Caldera F, Saha S, Wald A, Garmoe C, McCrone S, Megna B, Ley D, Reichelderfer M, Hayney MS. Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients. Digestive Disease and Sciences. 2018 Jun; 63(6):1532-1540.  PMID: 29594970
  2. Caldera F, Misch A, Saha S, Wald A, Zhang Y, Hubers J, Megna B, Ley D,  Reichelderfer M, Hayney MS. Immunosuppression does not Affect Antibody Concentrations to Measles, Mumps, and Rubella in Patients with Inflammatory Bowel Disease. Digestive Disease and Sciences. Oct 13, 2018. PMID: 30317494
  3. Caldera F, Saha S, Wald A, et al. 279 - Randomized Trial Evaluating the Immunogenicity of High Dose vs. Standard Dose Influenza Vaccine in IBD Patients on Anti-TNF Monotherapy. Inflamm Bowel Dis.   2020.  April; 26(4) 593-602. PMID: 31504526 
  4. Caldera F, Knutson KL, Saha S, Wald A, Phan HS, Chun K. Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls. Am J Gastroenterol. 2021:1-4. doi:10.14309/ajg.0000000000001570

 

 

2. Risk of vaccine preventable diseases in patients with inflammatory bowel disease.   Vaccine preventable diseases (VPD) are a common complication in patients with IBD.   I analyzed clinical trial data to show that the risk of herpes zoster is significantly higher in patients treated with tofacitinib compared to those on other conventional agents.   I have written two review articles discussing the risk of VPD in patients with IBD and ways to optimizing immunization strategies.

 

  1. Caldera F, Hayney M, Cross RK. Using number need to harm to put the risk of herpes zoster from tofacitinib in perspective. Inflamm Bowel Dis 2019. May 4;25(6):955-957. PMID:  30605536
  2. Caldera F, Ley D, Hayney MS, Farraye FA.   Optimizing Immunization Strategies in Patients with IBD.   Inflamm Bowel Dis.  2020 March 31.  PMID 32232388.
  3. Caldera F, Hayney MS, Farraye FA. How I Approach It Vaccination in Patients with Inflammatory Bowel Disease.  Am J Gastroenterol 2020.

 

 

3.0 Quality care in inflammatory bowel disease. Recent data suggest that patients with inflammatory bowel disease (IBD) do not receive appropriate preventive care. I designed a retrospective study that showed medically homed patients with IBD do not receive appropriate preventive care compared to those with rheumatoid arthritis. After the study, I designed a workbench in EPIC to increase preventive care for patients with IBD. I also wrote a review article for pharmacists on appropriate immunization for immunosuppressed patients with IBD.

 

  1. Caldera F, Saha S, Wald A, Cooley D, Zhanhai L, Yinqui Z, Bartels M Comparing Quality Care for Inflammatory Bowel Disease Patients with Regular Primary Care: Opportunities for Improvement by Collaboration Expert Review Gastroenterology & Hepatology 2016 Jun;10 (6) 759-66. PMID: 27029237
  2. Caldera F, Saha S, Hayney M. Vaccination of Patients with Inflammatory Bowel Disease. Journal of American Pharmacists Association 2016. Sept-Oct; 56(5) 591-3. PMID: 27594110

 

 

Complete list of published work in My Bibliography (total publications 51):  https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/44128311/?sort=date&direction=ascending

 

 

 

 

 

 

 

 

 

 

 

 

 

4. Ongoing Research Support             

 

Takeda Pharmaceuticals                                                                                                                                                          04/01/2021-04/01/22                                          Prospective study evaluating the safety and immunogenicity of COVID-19 vaccine in patients with inflammatory bowel disease.

The goal is to evaluate the humoral and cell mediated immune response to COVID-19vaccines in patients with inflammatory bowel disease.

Role:  Principal investigator.

 

 

Pfizer                                                                                     Wasan (PI)                                                                                                  09/01/2019-06/30/22

A pilot study evaluating immunogenicity of herpes zoster subunit vaccine in inflammatory bowel disease patients treated with tofacitinib.

The goal of this study is to evaluate humoral and cell mediated immunity in inflammatory bowel disease patients on tofacinitib who receive the two-dose herpes zoster vaccine.

Role: Co-Investigator

 

Takeda                                                                                     Caldera (PI)                                                                                     01/18/2019- 09/30/22

A pilot study evaluating immunogenicity of herpes zoster subunit vaccine in inflammatory bowel disease patients treated with vedolizumab.

The goal of this study is to evaluate humoral and cell mediated immunity in inflammatory bowel disease patients on vedolizumab who receive the two-dose herpes zoster vaccine.

Role: PI

 

Completed Research Support :

 

ICTR Pilot Grant                                          Calder              a (PI)                                                                                                   07/01/2017-04/30/19

University of Wisconsin Institue for Clinical & Translational Research (Pilot

Identifying inflammatory bowel disease patients with altered immunity at risk for herpes zoster.

The goal of this study was to evaluate if young, non-immunosuppressed inflammatory bowel disease patients are at higher risk for herpes zoster.

Role: PI

 

ACG Pilot Grant                                                                                                                                                                                                                                                           

American College of Gastroenterology   Caldera (PI)                                          07/01/2017-06/30/18

Identifying young immunosuppressed inflammatory bowel disease patients at risk for herpes zoster.

The goal of this study was to evaluate if young immunosuppressed inflammatory bowel disease patients are at higher risk for herpes zoster and might benefit from early herpes zoster immunization.

Role: PI